Novo Holdings Insmed Inc Transaction History

Novo Holdings

$1.43 Billion
Q3 2024

A detailed history of Novo Holdings transactions in Insmed Inc stock. As of the latest transaction made, Novo Holdings holds 724,666 shares of INSM stock, worth $48.8 Million. This represents 3.7% of its overall portfolio holdings.

Number of Shares

724,666

Previous 800,000 9.42%

Holding current value

$48.8 Million

Previous $53.6 Million 1.31%

% of portfolio

3.7%

Previous 3.83%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$62.0 - $79.01 $4.67 Million - $5.95 Million	-75,334 Reduced 9.42%	724,666 $52.9 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $11.9 Million - $37.6 Million	-539,304 Reduced 40.27%	800,000 $53.6 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $8.12 Million - $10.8 Million	499,304 Added 59.44%	1,339,304 $22.8 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $1.19 Million - $1.62 Million	70,000 Added 9.09%	840,000 $16.8 Million
Q2 2022 Aug 15, 2022	BUY	$17.07 - $25.71 $1.1 Million - $1.65 Million	64,162 Added 9.09%	770,000 $15.2 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $204,159 - $281,243	9,998 Added 1.44%	705,838 $16.6 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $5.78 Million - $8.61 Million	239,209 Added 52.39%	695,840 $19.8 Million
Q1 2021 May 17, 2021	BUY	$32.28 - $44.3 $856,194 - $1.18 Million	26,524 Added 6.17%	456,631 $15.6 Million
Q2 2020 Aug 14, 2020	BUY	$14.11 - $29.42 $6.07 Million - $12.7 Million	430,107 New	430,107 $11.8 Million

Others Institutions Holding INSM

# of Institutions

451

Shares Held

171M

Call Options Held

5.78M

Put Options Held

5.15M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.11B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.

Account